Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesStoke Therapeutics Inc

Stoke Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
26.54 USD 0.47 ( 1.80%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1160111
Market Cap
733.07M

Momentum Score

…

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
25.96
Low
26.72
High
52 Week Price Range
3.35
Low
16.66
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
26.07
Dividend Yield
-
Revenue TTM
7.84M
Revenue Per Share
0.17
Gross Profit TTM
12.40M
Debt / Equity
0.04
ROE
-61.29%
Net Debt
-184.61M
ROCE
-53.62%
Diluted EPS TTM
-2.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -101.07M -85.81M -52.24M -32.33M -12.52M
Minority interest - - - - 0.00M
Net income -93.11M -84.71M -50.61M -28.52M -12.52M
Selling general administrative 38.92M 31.90M 20.85M 11.91M 4.41M
Gross profit 12.40M - - - 0.00M
Reconciled depreciation 1.55M 0.97M 0.89M 0.45M 0.21M
Ebit -105.90M -87.04M -53.93M -36.13M -12.78M
Ebitda -104.36M -86.06M -53.04M -35.68M -12.57M
Depreciation and amortization 1.55M 0.97M 0.89M 0.45M 0.21M
Non operating income net other 0.17M 0.14M 0.80M - -
Operating income -104.36M -86.06M -53.04M -35.68M -12.78M
Other operating expenses 116.76M 86.06M 53.04M 35.68M 12.78M
Interest expense 3.12M 0.12M 0.00M 0.00M 0.00M
Interest income - 0.12M 0.74M 3.35M 0.27M
Net interest income 3.12M 0.12M 0.74M 3.35M 0.27M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense -7.96M -1.09M -1.63M -3.80M 0.26M
Total revenue 12.40M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 116.76M 86.06M 53.04M 35.68M 12.78M
Cost of revenue - - - - 0.00M
Total other income expense net 3.29M 0.26M 0.80M 3.35M -0.01M
Discontinued operations - - - - 0.00M
Net income from continuing ops -101.07M -85.81M -52.24M -32.33M -12.52M
Net income applicable to common shares -101.07M -85.81M -52.24M -32.33M -12.52M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 228.34M 256.07M 238.87M 297.93M 228.75M
Other current assets 13.88M 2.96M 9.28M 6.62M 3.28M
Total liab 68.78M 71.22M 21.09M 11.85M 4.32M
Total stockholder equity 159.56M 184.85M 217.78M 286.08M 224.43M
Deferred long term liab - 36.86M - - -
Other current liab 11.75M 13.39M 0.54M 9.93M 3.35M
Common stock 0.01M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -401.85M -297.15M -196.08M -110.28M -58.03M
Other liab - 37.11M 3.95M 0.34M 0.22M
Other assets - 0.57M 248.51M 1.32M 0.20M
Cash 191.44M 113.56M 144.90M 287.31M 222.47M
Total current liabilities 30.82M 31.39M 17.14M 11.43M 4.10M
Current deferred revenue 15.31M 14.88M 12.71M - -
Net debt -184.61M -111.20M -143.39M -287.31M -222.47M
Short term debt 2.06M 2.36M 1.51M - -
Short long term debt total 6.83M 2.36M 1.51M - -
Other stockholder equity 561.43M 483.17M 414.02M 396.35M 282.46M
Property plant equipment - 6.67M 9.08M 2.67M 2.51M
Total current assets 215.34M 244.07M 229.22M 293.93M 226.03M
Net tangible assets - 184.85M 217.78M 286.08M 224.43M
Short term investments 9.95M 116.04M 74.92M - -
Net receivables 0.06M 0.59M 0.13M 0.01M 0.28M
Inventory - 10.93M -74.92M - -
Accounts payable 1.70M 0.77M 2.38M 1.50M 0.75M
Accumulated other comprehensive income -0.02M -1.18M -0.17M - -0.81M
Common stock total equity - 0.00M 0.00M 0.00M 0.00M
Retained earnings total equity - -297.15M -196.08M -110.28M -
Non currrent assets other 0.57M 0.57M 0.57M 0.20M 0.20M
Non current assets total 13.00M 12.00M 9.65M 4.00M 2.72M
Capital lease obligations 2.06M 2.36M 1.51M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -41.92M -75.23M -1.05M -1.63M -0.93M
Change to liabilities 48.21M 2.90M 5.20M 0.89M 1.74M
Total cashflows from investing activities -45.88M -76.43M -1.05M -1.63M -0.93M
Net borrowings - - -0.18M - 0.00M
Total cash from financing activities 46.41M 1.28M 108.11M 149.76M 115.64M
Change to operating activities -5.18M -2.85M -2.88M -2.00M -0.64M
Net income -101.07M -85.81M -52.24M -32.33M -12.52M
Change in cash -31.34M -142.05M 64.84M 117.07M 103.75M
Begin period cash flow 145.46M 287.51M 222.68M 105.60M 1.85M
End period cash flow 114.12M 145.46M 287.51M 222.68M 105.60M
Total cash from operating activities -31.87M -66.91M -42.22M -31.05M -10.96M
Issuance of capital stock 45.34M 0.00M 105.40M 151.91M 116.02M
Depreciation 1.55M 0.97M 0.89M 0.45M 0.21M
Other cashflows from investing activities - - - 0.00M 0.01M
Dividends paid - - - - 0.00M
Change to inventory - - - - 0.00M
Change to account receivables - - - - 0.00M
Sale purchase of stock 1.06M 1.29M 108.29M 152.23M 116.02M
Other cashflows from financing activities 1.06M 1.28M 2.71M -2.15M 115.62M
Change to netincome 22.85M 16.48M 5.77M 1.93M 0.25M
Capital expenditures 3.96M 1.20M 1.05M 1.64M 0.94M
Cash flows other operating -3.40M -1.45M -1.84M - -
Cash and cash equivalents changes -31.34M -142.05M 64.84M - -
Change in working capital 43.02M 0.05M 2.33M -1.10M 1.09M
Stock based compensation 22.85M 16.45M 5.77M 1.92M 0.24M
Other non cash items 1.78M 1.26M 1.04M 0.00M 0.01M
Free cash flow -35.83M -68.11M -43.27M -32.69M -11.90M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
STOK
Stoke Therapeutics Inc		 0.47
1.80%		 26.54 - - 75.43 4.15 52.72 -4.12
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Stoke Therapeutics Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

45 Wiggins Avenue, Bedford, MA, United States, 01730

781 430 8200

https://www.stoketherapeutics.com

110

Name Title Year Born
Dr. Edward M. Kaye M.D., Ph.D. CEO & Director 1949
Dr. Adrian R. Krainer Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board 1959
Mr. Stephen J. Tulipano CPA, CPA, MBA Chief Financial Officer 1959
Dr. Barry S. Ticho FACC, M.D., Ph.D. Chief Medical Officer 1961
Ms. Isabel Aznarez Ph.D. Co-Founder & Group VP of Discovery Research 1973
Dr. Huw M. Nash Ph.D. COO & Chief Bus. Officer 1967
Mr. Eric Rojas Head of Investor Relations NA
Mr. Jonathan Allan J.D. Gen. Counsel NA
Ms. Dawn Kalmar Chief Communications Officer 1978
Ms. Joan Wood Chief HR Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…